These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23400950)

  • 1. The soluble isoform of CTLA-4 as a regulator of T-cell responses.
    Ward FJ; Dahal LN; Wijesekera SK; Abdul-Jawad SK; Kaewarpai T; Xu H; Vickers MA; Barker RN
    Eur J Immunol; 2013 May; 43(5):1274-85. PubMed ID: 23400950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.
    Dahal LN; Basu N; Youssef H; Khanolkar RC; Barker RN; Erwig LP; Ward FJ
    Arthritis Res Ther; 2016 Aug; 18():180. PubMed ID: 27487771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
    Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
    PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma.
    Khanolkar RC; Zhang C; Al-Fatyan F; Lawson L; Depasquale I; Meredith FM; Muller F; Nicolson M; Dahal LN; Abu-Eid R; Rajpara S; Barker RN; Ormerod AD; Ward FJ
    Front Immunol; 2021; 12():763877. PubMed ID: 35069536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
    Ward FJ; Dahal LN; Khanolkar RC; Shankar SP; Barker RN
    Immunotherapy; 2014; 6(10):1073-84. PubMed ID: 25428646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
    Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
    Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.
    Kennedy PT; Saulters EL; Duckworth AD; Lim YJ; Woolley JF; Slupsky JR; Cragg MS; Ward FJ; Dahal LN
    Mol Ther; 2024 Feb; 32(2):457-468. PubMed ID: 38053333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice.
    Mourich DV; Oda SK; Schnell FJ; Crumley SL; Hauck LL; Moentenich CA; Marshall NB; Hinrichs DJ; Iversen PL
    Nucleic Acid Ther; 2014 Apr; 24(2):114-26. PubMed ID: 24494586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
    Wing K; Yamaguchi T; Sakaguchi S
    Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
    Pruitt SK; Boczkowski D; de Rosa N; Haley NR; Morse MA; Tyler DS; Dannull J; Nair S
    Eur J Immunol; 2011 Dec; 41(12):3553-63. PubMed ID: 22028176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles.
    Esposito L; Hunter KM; Clark J; Rainbow DB; Stevens H; Denesha J; Duley S; Dawson S; Coleman G; Nutland S; Bell GL; Moran C; Pekalski M; Todd JA; Wicker LS
    J Immunol; 2014 Jul; 193(2):889-900. PubMed ID: 24928993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses.
    Simone R; Pesce G; Antola P; Rumbullaku M; Bagnasco M; Bizzaro N; Saverino D
    Biomed Res Int; 2014; 2014():215763. PubMed ID: 24605322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.
    Walker LS; Sansom DM
    Nat Rev Immunol; 2011 Nov; 11(12):852-63. PubMed ID: 22116087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function.
    Gerold KD; Zheng P; Rainbow DB; Zernecke A; Wicker LS; Kissler S
    Diabetes; 2011 Jul; 60(7):1955-63. PubMed ID: 21602513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner.
    Yu R; Jin L; Li F; Fujimoto M; Wei Q; Lin Z; Ren X; Jin Q; Li H; Meng F; Jin G
    J Dermatol Sci; 2020 Sep; 99(3):193-202. PubMed ID: 32859456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of co-inhibitory signals driven by CTLA-4 in immune system].
    Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA
    Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.
    Tsuji-Takayama K; Suzuki M; Yamamoto M; Harashima A; Okochi A; Otani T; Inoue T; Sugimoto A; Motoda R; Yamasaki F; Nakamura S; Kibata M
    Exp Hematol; 2008 Feb; 36(2):181-92. PubMed ID: 18023521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.